FDA investigation of RU-486 death reports
FDA is "obtaining more information" about a recent death associated with Danco's abortifacient Mifeprex (mifepristone). Since the drug's approval in September 2000, FDA has received three other reports (one each in the U.S., Canada and U.K.) of women who died and were taking mifepristone, but says it is "unlikely that these deaths were caused by" the drug. FDA will "continue to monitor adverse events with this particular drug, as it does with all drugs," the agency says...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.